Decreased sugar/carb cravings have been reported.
Communication to your brain allowing you to feel less hungry through the week.
Which allows you to fill in smaller portion of food
Studies show that medication improves A1C levels.
Helps treat insulin resistance
During a weight loss trial of close to 2,000 obese adults the average weight loss was 15 % of their body weight during their course of treatment with semaglutide.
The most reported side effects are nausea, constipation and diarrhea. Other side effects may include but not limited to; burping, heartburn and least common abdominal pain.
No, we do not push or recommend specific dieting during semaglutide treatment. We do however recommend changing any unhealthy habits to promote long term lifestyle changes to help sustain your healthy weight.
Everyones weight loss journeys take different amount of time to reach their goals. During your consults we can discuss your weight and the goals you are wanting to achieve. Generally we like to see you reach a healthy goal weight and we will help maintain that weight for some time before we taper down or take you off the medication.
Semaglutide is a peptide that mimicks GLP-1s which are powerful hormones made by your small intestines. These hormones send signals to your brain and other body parts like stomach, liver, and pancreas to regulate your insulin release, glucose and also help regulate your appetite and digestion. These mechanisms of actions allow you to feel full on smaller portions of food, decreasing overall cravings, and stabilizing blood sugar levels.
Generally, it can take 7-14 days to get your prescription shipped to you. There has been an influx
of prescriptions for semaglutide which creates a demand. Pharmacies are trying their best to keep up with this demand. With that being said we like to keep in communication with you for refills in order to get your medication shipped to you on time.
The prescribing information for Wegovy (Semaglutide) contains a boxed warning to inform healthcare professionals and patients about the potential risk of thyroid C-cell tumors. Wegovy (Semaglutide) should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with a rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).